Adamas Pharmaceuticals Inc

ADMS 
(NASDAQ) 
 
$ 23.41
Updated 14/08/2018
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 70,983
High $ 23.52
Low $ 22.98
Open $ 23.37
ISIN
Prev close $ 23.41
# of shares 27.19M
Market cap 636.53M USD
Intraday

Market closed
Adamas Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  23.41 -4.8% Stock price decreasing -13.5% Stock price decreasing -25.6% Stock price decreasing -32.0% Stock price decreasing 59.5% Stock price increasing
Powered by TradingView

News about Adamas Pharmaceuticals Inc

  • English
  • Regulatory news

Company profile

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. Adamas generates its revenues from the United States.

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
15 August 2018 10:12:33
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180815.1 - EUROWEB3 - 2018-08-15 11:12:33 - 2018-08-15 10:12:33 - 1000 - Website: OKAY